Oncogenic KRAS has also been shown to induce GM-CSF in pancreatic cancer, resulting in the expansion of immunosuppressive Gr1+CD11b+ myeloid cells and inhibition of T-cell–mediated tumor control (32). This evidence concerns the gene KRAS and familial pancreatic carcinoma.